Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have been diagnosed with a specific eye condition called neovascular age-related macular degeneration (nAMD), and whose treating doctor has prescribed a medication called Brolucizumab for them as per approved guidelines.
- People who have been clearly told about the purpose and nature of the study and have agreed in writing to take part.
Who may not be able to join:
- People who have a known allergy or sensitivity to Brolucizumab or any of its ingredients, or who have an active or suspected infection in or around the eye, or who have active inflammation inside the eye.
- People who are currently taking part in another clinical trial involving an investigational (unapproved or experimental) drug.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events at 12 weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.